ETIDIOH - NEW

{Excerpt} Highlights •  A new strain of Lassa virus (LASV) was successfully isolated and characterized. •  The combination of ribavirin and LHF-535 has been demonstrated to exhibit synergistic effects in inhibiting LASV. •  The findings provide new directions for the development of antiviral drugs and vaccines for Lassa fever. Dear Editor, Lassa virus (LASV) is the causative agent of the acute viral hemorrhagic Lassa fever (LF), which is classified into Mammarenavirus within the Arenaviridae family , with a single-stranded, negative-sense, bi-segmented RNA genome. Due to its high pathogenicity and lethality , LASV is considered as a priority threat to public health , with an estimated cases of 300,000 infections and 5,000 deaths annually . LASV was first isolated and described as a clinical entity in 1969 in Lassa, Nigeria (Garry, 2023). LASV isolates of different geographic and host origins are highly diverse in genomic sequences and phylogenetically classified into up t...

Summary The 2024 Nipah outbreak in Kerala, India —its fifth in six years—and the recurring annual outbreaks in Bangladesh underscore the persistent threat posed by the Nipah virus (NiV) in the region. With a high mortality rate, human-to-human transmission potential , and the widespread presence of Pteropus bats , the natural reservoir, NiV remains a significant epidemic threat . Despite being a WHO priority pathogen , there has been no systematic effort to improve patient care for NiVD, leading to consistently poor outcomes . Current care relies on supportive measures and the ‘ compassionate use ’ of unapproved drugs like ribavirin and remdesivir . Drugs used ‘off-label’ during outbreaks can become the ‘standard of care’ without robust evidence of their safety or efficacy, complicating the testing of new therapies and perpetuating uncertainty about their true effectiveness. To improve NiVD care, we propose four key strategies: 1) Enhance early case detection , 2) optimize supportive c...